{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang L"],"funding":["NIBIB NIH HHS","NCI NIH HHS"],"pagination":["9874"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4428068"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5"],"pubmed_abstract":["There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As(3+))-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As(3+), the active form of ATO, and Mn(2+), the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO."],"journal":["Scientific reports"],"pubmed_title":["Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs."],"pmcid":["PMC4428068"],"funding_grant_id":["P50 CA108961","R01 CA194578","P41-EB015908","R21 CA141348","CA108961","P41 EB015908","U24 CA126608","5P30 CA 142543-05","P30 CA142543"],"pubmed_authors":["Mason RP","Zhang Z","Zhang L","Zhao D","Sarkaria JN"],"additional_accession":[]},"is_claimable":false,"name":"Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs.","description":"There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As(3+))-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As(3+), the active form of ATO, and Mn(2+), the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 May","modification":"2021-03-06T08:41:02Z","creation":"2019-03-27T01:51:25Z"},"accession":"S-EPMC4428068","cross_references":{"pubmed":["25962872"],"doi":["10.1038/srep09874"]}}